I
Innovita Biological Technology Co Ltd
SSE:688253
Innovita Biological Technology Co Ltd
SSE:688253
Price:
35.01
CNY
-2.97%
Market Closed
Market Cap:
¥4.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Innovita Biological Technology Co Ltd
SSE:688253
|
CN |
|
American Financial Group Inc
NYSE:AFG
|
US |
|
N
|
Nordic Technology Group AS
OSE:NTG
|
NO |
|
Kolinpharma SpA
MIL:KIP
|
IT |
Cash Flow Statement
Cash Flow Statement
Innovita Biological Technology Co Ltd
Innovita Biological Technology Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
0
|
0
|
0
|
|
| Cash Taxes Paid |
(43)
|
(37)
|
(30)
|
(28)
|
(34)
|
(43)
|
(44)
|
(48)
|
(46)
|
(77)
|
(89)
|
(89)
|
(91)
|
(91)
|
(68)
|
(51)
|
|
| Change in Working Capital |
(131)
|
(114)
|
(119)
|
(120)
|
(153)
|
(135)
|
(119)
|
(110)
|
(116)
|
(141)
|
(161)
|
(174)
|
(167)
|
(180)
|
(200)
|
(203)
|
|
| Cash from Operating Activities |
106
N/A
|
87
-18%
|
100
+16%
|
100
0%
|
126
+26%
|
85
-33%
|
91
+7%
|
126
+39%
|
260
+106%
|
413
+59%
|
409
-1%
|
433
+6%
|
305
-29%
|
296
-3%
|
234
-21%
|
177
-24%
|
|
| Investing Cash Flow | |||||||||||||||||
| Capital Expenditures |
(64)
|
(39)
|
(36)
|
(38)
|
(58)
|
(58)
|
(45)
|
(37)
|
(17)
|
(22)
|
(24)
|
(26)
|
(36)
|
(34)
|
(37)
|
(40)
|
|
| Other Items |
24
|
(8)
|
(0)
|
(853)
|
(1 028)
|
(853)
|
(1 023)
|
(346)
|
(412)
|
(583)
|
(156)
|
35
|
(27)
|
2
|
(195)
|
(299)
|
|
| Cash from Investing Activities |
(39)
N/A
|
(47)
-20%
|
(37)
+22%
|
(891)
-2 330%
|
(1 086)
-22%
|
(910)
+16%
|
(1 069)
-17%
|
(383)
+64%
|
(429)
-12%
|
(605)
-41%
|
(180)
+70%
|
9
N/A
|
(63)
N/A
|
(32)
+48%
|
(233)
-617%
|
(339)
-46%
|
|
| Financing Cash Flow | |||||||||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
820
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
12
|
|
| Net Issuance of Debt |
(8)
|
10
|
10
|
18
|
18
|
(2)
|
(10)
|
(18)
|
(18)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Paid for Dividends |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(25)
|
(24)
|
(23)
|
0
|
(52)
|
(53)
|
(54)
|
0
|
(75)
|
(75)
|
|
| Other |
(51)
|
(51)
|
(3)
|
808
|
(22)
|
798
|
797
|
(13)
|
(4)
|
(4)
|
(4)
|
1
|
(54)
|
(81)
|
(82)
|
(86)
|
|
| Cash from Financing Activities |
(60)
N/A
|
(41)
+31%
|
7
N/A
|
826
+12 598%
|
816
-1%
|
795
-3%
|
763
-4%
|
(55)
N/A
|
(44)
+20%
|
(35)
+22%
|
(56)
-62%
|
(52)
+7%
|
(103)
-98%
|
(130)
-27%
|
(151)
-16%
|
(150)
+1%
|
|
| Change in Cash | |||||||||||||||||
| Effect of Foreign Exchange Rates |
(10)
|
(14)
|
17
|
39
|
43
|
41
|
22
|
(1)
|
1
|
5
|
(0)
|
(2)
|
2
|
1
|
1
|
2
|
|
| Net Change in Cash |
(2)
N/A
|
(16)
-581%
|
88
N/A
|
74
-15%
|
(101)
N/A
|
10
N/A
|
(193)
N/A
|
(313)
-62%
|
(212)
+32%
|
(222)
-5%
|
173
N/A
|
388
+125%
|
141
-64%
|
135
-5%
|
(149)
N/A
|
(310)
-107%
|
|
| Free Cash Flow | |||||||||||||||||
| Free Cash Flow |
43
N/A
|
48
+12%
|
64
+35%
|
62
-3%
|
69
+10%
|
27
-61%
|
46
+69%
|
90
+97%
|
243
+171%
|
390
+61%
|
384
-1%
|
406
+6%
|
269
-34%
|
262
-3%
|
197
-25%
|
137
-30%
|
|
Switch to:
Switch to:
See Also
Discover More
